La catena delle opzioni mostra i dati chiave delle opzioni azionarie di PowerFleet a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per PowerFleet..

PowerFleet (NASDAQ:AIOT) Azioni, Catena delle Opzioni

POWERFLEET INC

PowerFleet

PowerFleet Inc is engaged in Internet-of-Things (IoT) solutions providing valuable business intelligence for managing high-value enterprise assets that improve operational efficiencies. It provide critical information that powers unified operations throughout organizations. It is solving the challenge of inefficient data collection, real-time visibility, and analysis that leads to transformative business operations. Its SaaS cloud-based applications take data from IoT devices and ecosystem of third-party and partner applications to present actionable information for customer.

Irving,,Texas,,Usa,-,March,19,,2022:,Lennar,Dfw,Division

Pre-Market Outlook

AIOT

APPS

Un maxi-buyback scuote i mercati prima delle trimestrali più attese. L&#39;attenzione degli investitori è rivolta a 5 nomi chiave.

5 titoli pronti a scattare tra trimestrali chiave e annunci a sorpresa

PowerFleet Inc

WIIM

UNCY

Unicycive Therapeutics shares are trading lower after the company announced a 1-for-10 reverse stock split effective June 20, 2025.

News

CLSD

Clearside Biomedical Highlights Suprachoroidal Platform And CLS-AX Advancements At Clinical Trials At The Summit Meeting

OFIX

Orthofix Announces Global Launch Of TrueLok Elevate To Address Diabetic Ulcers And Limb Preservation Needs

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) will reportedly begin sales operations for its Semitruck in Europe, almost a decade after the product's unveiling, as the company faces <a href="https://www.benzinga.com/news/topics/25/06/45716179/teslas-china-sales-slump-while-byd-and-li-auto-post-strong-gains-report">sales declines</a> throughout multiple markets.
What Happened: Tesla has reportedly hired Usuf Schermo to head its Semitruck operations in the region, Electrek reported <a href="https://electrek.co/2025/06/17/tesla-start-selling-semi-electric-truck-europe/">on</a> Tuesday.
Schermo previously worked for electric Semitruck manufacturer Volta Trucks, where he served as the company's head of sales in Germany, the report suggests.
As per his LinkedIn profile, Schermo's official title at Tesla is Head of Business Operations at Tesla Semi EMEA, which could potentially mean Elon Musk's EV giant also plans to expand operations in the Middle East and Africa.
Why It Matters: News of the expansion comes in as Tesla has shared that its first batch of the Semitrucks will roll out from the company's Nevada Gigafactory by the <a href="https://www.benzinga.com/tech/25/04/45060435/teslas-first-batch-of-semi-trucks-to-roll-out-from-nevada-plant-by-late-2025-despite-disruption-from-trumps-145-tariffs">end of the year</a>. The Nevada facility can produce over 50,000 units of the Semitruck annually.
However, it could prove to be difficult as recently, the Semitruck <a href="https://www.benzinga.com/25/04/44831422/donald-trumps-145-tariffs-on-china-could-disrupt-teslas-cybercab-semi-production-report">productions were disrupted </a>by U.S. President Donald Trump's tariffs on China amid the ongoing trade tensions between the two countries.
Interestingly, the European expansion comes when Musk's company has been grappling with <a href="https://www.benzinga.com/markets/eurozone/25/06/45736798/tesla-sales-hit-3-year-low-in-this-european-nation-despite-musks-claims-of-no-demand-problem">declining sales in the region</a>, mostly attributed to Musk's endorsement of right-wing political ideals as well as his close association with the Trump administration.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="208" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17062509/TSLA-JUN-17-2025-2-1024x208.jpg" alt="" class="wp-image-952002" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17062509/TSLA-JUN-17-2025-2-1024x208.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17062509/TSLA-JUN-17-2025-2-300x61.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17062509/TSLA-JUN-17-2025-2-768x156.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17062509/TSLA-JUN-17-2025-2-1536x312.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17062509/TSLA-JUN-17-2025-2.jpg 1549w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Tesla scores well on Momentum, Quality and Growth metrics. However, the stock offers poor Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge</a> today!
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45965638/amid-trumps-anti-ev-push-senate-republicans-propose-tax-bill-to-axe-7500-ev-credit">Amid Trump&#8217;s Anti-EV Push, Senate Republicans Propose Tax Bill To Axe $7500 EV Credit</a></li>
</ul>
Photo courtesy: Ken Wolter / Shutterstock.com

Tech

TSLA

Tesla Looks To Rollout Semitruck In Europe Amid Elon Musk's Politics-Induced Sales Rout

Partnership includes research collaboration, development of commercial use cases, and collaborative efforts for acquisition of a D-Wave Advantage2&#x2122; system at Yonsei University International Campus
D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) ("D-Wave" or the "Company"), a leader in quantum computing systems, software, and services, today announced that it has signed a memorandum of understanding (MOU) with Yonsei University and Incheon Metropolitan City, designed to accelerate the exploration, adoption and usage of quantum computing in South Korea.
Under the terms of the MOU, the three organizations intend to work together to advance mutual research and talent development for quantum computing, provide access to D-Wave's quantum computing technology, and collaborate on development of use cases in biotechnology, materials science and other areas. In addition, the MOU facilitates the organizations' efforts towards the acquisition of a D-Wave Advantage2 system at the Yonsei University International Campus in Songdo, Yeonsu-gu, Incheon.

QBTS

D-Wave Quantum Signs MOU With Yonsei University And Incheon Metropolitan City, To Accelerate Exploration, Adoption And Usage Of Quantum Computing In South Korea

ACXP

Acurx Pharmaceuticals shares are trading higher after the company announced publication of its Phase 2 ibezapolstat study results in The Lancet.

ANTA

Antalpha Platform Projects Q2 Revenues Between $16M-$17M, Representing A Growth Rate Of 40%-50% YoY

APPS: 16% &#x7C; <a href="https://www.benzinga.com/node/45960999">Digital Turbine shares are trading higher after reporting better-than-expected Q4 EPS and sales.</a>
&nbsp;
RDW: -13% &#x7C; <a href="https://www.benzinga.com/node/45961312">Redwire shares are trading lower after the company announced a $200 million common stock offering.</a>
&nbsp;
CERO: 139% &#x7C; <a href="https://www.benzinga.com/node/45968990">CERo Therapeutics shares are trading higher after the company received FDA Orphan Drug Designation for CER-1236 for the treatment of acute myeloid leukemia.</a>

Movers

Trading Ideas

CERO

Market-Moving News for June 17th

Moolec Science SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLEC#NASDAQ">MLEC</a>) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced the successful closing of its previously announced strategic business combination (the "Business Combination") with Bioceres Group Limited ("Bioceres Group"), Gentle Technologies Corp ("Gentle Tech"), and Nutrecon LLC ("Nutrecon"). With the closing, Moolec emerges as the parent company of a significantly expanded and enhanced enterprise at the forefront of sustainable life sciences and food-tech innovation.
The Business Combination, initially announced on April 17, 2025, was ratified by Moolec shareholders at the Extraordinary General Meeting ("EGM") held on June 16, with ~77% of the outstanding shares present at the meeting, and ~98% of the votes cast were in favor of the transaction.
Under the terms of the transaction, Bioceres Group shareholders have exchanged their equity ownership for approximately 6.9 million shares of Moolec. The shareholders of 100% of Nutrecon and 50% of Gentle Tech have received, in exchange for their ownership in these entities, approximately 0.65 million shares of Moolec and 0.5 million Moolec private warrants, each with a strike price of $20.00.
The combined company will continue operating under the name Moolec Science, with its securities trading on NASDAQ under the ticker symbols "MLEC" and "MLECW".

Management

MLEC

Moolec Science Closes Strategic Business Combination With Bioceres Group, Gentle Tech, And Nutrecon; Continues Trading As "MLEC" And "MLECW" On NASDAQ; Names Alejandro Antalich CEO

Mali's Bamako Commercial Court on Monday placed the Loulo-Gounkoto gold complex, one of Barrick Mining's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/B#NYSE">B</a>) largest assets, into state control for six months. After a <a target="_blank" href="https://www.benzinga.com/markets/commodities/25/06/45746216/third-delay-in-mali-court-battle-over-barricks-gold-complex" rel="noreferrer noopener">prolonged standoff over taxation</a>, Mali appointed former health minister Suomana Makadji as provisional administrator.
"Justice was neither heard, nor served," Issaka Keita, one of Barrick's lawyers, said after the ruling, according <a target="_blank" href="https://www.reuters.com/world/africa/mali-court-appoints-provisional-administrator-run-barrick-minings-complex-2025-06-16/" rel="noreferrer noopener">to</a> Reuters.
The Loulo-Gounkoto complex represents one of the largest mining operations in Mali and is a crucial component of Barrick's portfolio in Africa.
In 2024, it was responsible for 14% of Barrick's total gold production globally and generated $949 million in revenue during the first three quarters of that year.
Also Read: <a href="https://www.benzinga.com//node/45731042">3 Gold Alternatives Set To Soar Next</a>
Barrick has subsequently excluded its Mali forecast from the production guidance due to the persistent uncertainty. The ongoing dispute between Barrick and the military-led government of Mali has been in effect since 2023, originating from the <a target="_blank" href="https://www.benzinga.com/news/guidance/24/12/42516175/barrick-warns-about-destabilization-in-mali-could-halt-one-of-its-largest-mines" rel="noreferrer noopener">enforcement of a new mining code</a>.
The revised legislation increases state participation in mining ventures and imposes higher taxes, with Mali seeking to increase royalties from 20% to 35%. While Barrick contends that it has honored its obligations under previous agreements, the government insists that renegotiation is necessary under the new legal framework.
Tensions escalated in late 2024 when officials prohibited gold exports and confiscated three metric tons of gold from Barrick's subsidiaries. In retaliation, Barrick <a target="_blank" href="https://www.benzinga.com/news/global/25/01/42823362/barrick-gold-warns-about-production-suspension-in-mali" rel="noreferrer noopener">halted operations</a> in January.
Despite both parties engaging in negotiations, Mali's decision to appoint a provisional administrator suggests its intention to resume mining operations, albeit under its own terms.&nbsp;
Barrick has challenged the government's actions as "unjustified" and has stated its intention to appeal the court's decision. In the meantime, it is seeking international arbitration via the International Centre for Settlement of Investment Disputes.
"It requires a foundation of mutual respect, sound governance, and long-term partnership," the company said in its <a target="_blank" href="https://www.barrick.com/English/news/news-details/2025/barrick-holding-firm-through-ICSID-arbitration-amid-malian-court-ruling/default.aspx" rel="noreferrer noopener">latest statement</a>, while also condemning the detention of its employees as leverage in the negotiations.
Mali has <a target="_blank" href="https://www.benzinga.com/news/global/25/02/43588936/malian-gold-output-falls-23-as-new-mining-law-pressures-producers" rel="noreferrer noopener">struggled to maintain production levels</a> as Africa's third-largest gold producer. Gold production in 2024 fell by 23% to 51 metric tons from 66.5 metric tons in 2023.
Price Watch: Barrick closed at $21.41, dropping 0.83% for the day. The stock is up 38.4% year-to-date.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/guidance/25/06/45928561/gold-biggest-boom-in-decades-and-investors-are-still-missing-out" target="_blank" rel="noreferrer noopener">Gold's Biggest Boom In Decades—And Investors Are Still Missing Out</a></li>
</ul>
Photo by Below the Sky via Shutterstock

Government

Large Cap

Regulations

Emerging Markets

Commodities

Legal

Markets

Barrick's Top Gold Mine Placed Under State Control

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4450908-1&amp;h=1051678966&amp;u=https%3A%2F%2Ffreseniusmedicalcare.com%2Fen%2F&amp;a=Fresenius+Medical+Care">Fresenius Medical Care</a>&nbsp;(FME), the world's leading provider of products and services for people with kidney disease, today unveiled its new FME Reignite strategy at its Capital Markets Day in London. FME Reignite centers on value creation, based on three strategic elements: Reignite the core, Reignite growth and innovation and Reignite our culture.
<a href="https://mma.prnewswire.com/media/655917/FMC_Logo.html"><img src="https://mma.prnewswire.com/media/655917/FMC_Logo.jpg" alt="Fresenius Medical Care (PRNewsfoto/Fresenius Medical Care North Am)" /></a>
"FME Reignite sets the ambition to deliver both industry-leading outcomes and margins1 with above-market growth," said&nbsp;Helen Giza, Chief Executive Officer of Fresenius Medical Care. "We have executed on our three-year turnaround and transformation plan and delivered significant progress against our key performance metrics of margin1 improvement, FME25 savings and deleveraging. Based on attractive underlying business fundamentals and strong momentum, we have set profitability ambitions for 2030 at industry-leading margin1 levels and an ambition to lead kidney care through exceptional patient care and innovation."
Helen Giza added: "By leveraging the benefits of vertical integration across our three operating segments – Care Delivery, Care Enablement and Value-Based Care – we advance to industry-leading operating income margins1. We aspire to reach a mid-teens percent operating income margin1&nbsp;for Fresenius Medical Care by 2030. While we continue to invest in profitable growth and innovation in our core business and continue to further optimize our capital structure, we have the additional opportunity to reignite value creation for shareholders. We plan to return excess capital to our shareholders through a 30 to 40 percent dividend payout2 plus the opportunity for regular share buybacks. We will start in 2025 with an initial share buyback of EUR 1 billion within two years."
FME Reignite to shape the future
FME Reignite shapes the future of Fresenius Medical Care with three main elements.
REIGNITE THE CORE: delivering operational excellence with the Company´s core assets in its leading market positions. This will drive scalable, high-quality care to further enhance patient health, and increase agility and operational efficiency through further standardized and improved operations as well as focused investments in technology and special programs.
REIGNITE GROWTH AND INNOVATION: further enhancing clinic outcomes and patient safety; increasing R&amp;D efficiency with its global innovative platforms; setting a new standard of care with the U.S. launch of high-volume hemodiafiltration; growing the clinic network in targeted international markets and driving AI-powered transformation in patient care.
REIGNITE OUR CULTURE: with a focus on its people, Fresenius Medical Care has the ambition to become the employer of choice in healthcare, attracting, retaining and engaging the best talent with a passion to make an impact, while living its new core values: We care. We connect. We commit. This new culture statement embodies the values and behaviors that all leaders and employees of Fresenius Medical Care aspire for every day.
Hemodiafiltration and value-based care upside to fundamental volume drivers
In the global market the average annual growth for the number of dialysis patients is projected to be between 4 and 5 percent between 2025 and 2035. This includes an average annual patient number growth of 2 plus percent in the U.S. in the same timeframe. "The projection of dialysis patient growth numbers remains unchanged as our business fundamentals remain intact. The number of people on maintenance dialysis is expected to grow by 90 percent globally to 7 million people by 2035", said Franklin W. Maddux, M.D., Chief Global Medical Officer of Fresenius Medical Care.
Frank Maddux further commented: "Beyond the anticipated growth in patient numbers, we expect the introduction of high-volume hemodiafiltration in the U.S. and the benefits of value-based care to further accelerate the number of treatments. Future medical trends in favor of patient survival are preventive health, AI-based diagnostics, medications with survival benefits for CKD and ESRD patients and personalized medicine. Fresenius Medical Care is uniquely positioned to participate and benefit from these population trends." &nbsp;
Launch of 5008X machine enables HVHDF to be the new standard of care in the U.S.
Fresenius Medical Care shared further details of the upcoming U.S. market launch plan for its 5008X machine at the Capital Markets Day. Introducing high-volume hemodiafiltration (HVHDF) has the potential to transform the standard of care for kidney replacement therapies in the U.S. With the final FDA clearance secured, launch plans are underway for 2025 with full commercial launch following in 2026 with comprehensive considerations across all key stakeholders of the renal care community.
For CONVINCE&#x2A; study patients, survival benefits emerged after just 3 months of HVHDF treatment, as shown in the European study, resulting in 4.4 percent fewer deaths over 2.5 years of follow up. Other real-world evidence shows that this new therapy option also comes along with reduced hospitalization rates as well as improved quality of live and outcomes for patients, which is expected to reduce the number of missed treatments in the future.
By 2030, the Company expects to have replaced all existing 2008T dialysis machines in its own U.S. clinic network with the innovative 5008X machine, offering the new standard of care to all its eligible dialysis patients. Following an increasing penetration of HVHDF treatments, clinic operations are expected to benefit from reduced mortality rates, machine-related clinic labor and supply efficiencies and potential for reduced drug usage.
As the manufacturer of the 5008X machine, the first and until today only FDA-cleared hemodiafiltration machine, Fresenius Medical Care expects to benefit from its strong U.S. market leader position in the currently installed machine base and to further increase its captive market share in disposable products. Pricing of the 5008X machine is planned to reflect the innovative value that the Company has created for patients as well as for Care Delivery and 3rd party service providers.
Introducing Value-Based Care as separate operating segment Fresenius Medical Care announced the introduction of Value-Based Care (VBC) as a separate segment, formerly part of the Care Delivery segment. This will further enhance the transparency of the financial reporting and provide additional insights into an area that is growing in relevance. Value-Based Care generated revenue of EUR 1.8 billion in fiscal year 2024 in the U.S. The Value-Based Care segment comprises the value- and risk-based care programs with public and private payors in the U.S. to provide long-term care to CKD and ESRD patients.
The new segment leverages the power of vertical integration through the Company-wide use of patient and clinic data, treatment insights and medical innovation to provide high-quality care to further improve patient and quality of care outcomes. It supports practice management and relationships with around 2,200 partner nephrologists, while reducing total medical cost.
Industry-leading margins – 2030 margin aspirations The new FME Reignite strategy supports the Company's profitability aspirations on industry-leading levels. Fresenius Medical Care aspires to realize a mid-teens percent operating income1 margin by 2030.3
For Care Delivery and Care Enablement, the Company set the aspiration of a mid-teens percent operating income1&nbsp;margin. For Value-Based Care, Fresenius Medical Care set the aspiration of a low-single digit percent operating income1&nbsp;margin.
The Company announced additional EUR 300 million savings to be achieved through the expansion of its successful FME25 program by two years. The total program with its extension runs under the name 'FME25+'. For FME25+ the Company targets to realize EUR 1.05 billion of sustainable savings by the end of 2027, with one-time costs of a similar amount to be treated as special item to operating income. The expected sustainable savings will support the aspired operating income margin1 improvement.
Returning excess capital to shareholders
Fresenius Medical Care plans to further improve its strong operating cash flow generation in the coming years and REIGNITE VALUE CREATION for shareholders.
"In support of the FME Reignite strategy, the new capital allocation framework puts a clear focus on shareholder value generation," explained Martin Fischer, Chief Financial Officer of Fresenius Medical Care. "To invest in our core business for sustainable profitable growth, we plan between EUR 800 million and 1 billion of capex annually for the years 2025 to 2030. In parallel, we will further optimize our capital structure."
A strong balance sheet, financial flexibility and a commitment to a sustainable Investment Grade rating are key aspects of the financial policy. Reflecting the volatile macroeconomic environment, Fresenius Medical Care lowered its self-imposed target band for the net financial leverage to between 2.5x and 3.0x (before: 3.0x to 3.5x).
Martin Fischer added: "Through this clear set of priorities focused on value creation, we plan for attractive returns of excess capital to our shareholders. The new dividend policy foresees a stable and predictable dividend development, resulting in a 30 to 40 percent payout ratio2. With our share buyback program, we are excited to introduce an additional way of returning value to our shareholders, besides dividends. The new program will start in 2025 and comprise initial share buybacks of EUR 1 billion within two years. Our new capital allocation framework provides further opportunities for regular buybacks."

Fresenius Launches 'FME Reignite' With $1B Annual Capex Plan and $1.05B Cost Savings Target by 2027

SLRX

Salarius Pharmaceuticals shares are trading higher after the company disclosed it received an extension from the Nasdaq to regain compliance.

<ul>
<li>High-volume asset gives Company a foothold in one of the strongest performing retail corridors in the trade area</li>
<li>Acquisition positions Whitestone to benefit from upcoming development, driven by strong neighborhood dynamics</li>
</ul>

Whitestone REIT Acquires 5000 South Hulen In Fort Worth To Expand Presence In High-Performing Retail Corridor

Jones Trading analyst Debanjana Chatterjee initiates coverage on Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy rating and announces Price Target of $24.

Price Target

Initiation

Analyst Ratings

TBPH

Jones Trading Initiates Coverage On Theravance Biopharma with Buy Rating, Announces Price Target of $24

MOBX

Mobix Labs Says Customer Orders Exceed Shipments By 75% In the Previous Quarter

HC Wainwright &amp; Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) with a Buy and maintains $20 price target.

Reiteration

SLDB

HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $20 Price Target

Armada Acquisition Corp. II (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACIU#NASDAQ">AACIU</a>) (the "Company") announced today that, commencing June 24, 2025, holders of the 23,000,000 units sold in the Company's initial public offering may elect to separately trade shares of the Company's Class A ordinary shares and warrants included in the units. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Stock Market LLC ("Nasdaq") under the symbols "AACI" and "AACIW", respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Those units not separated will continue to trade on Nasdaq under the symbol "AACIU." Holders of units will need to have their brokers contact Continental Stock Transfer &amp; Trust Company, the Company's transfer agent, in order to separate the units into Class A ordinary shares and warrants.
The units were initially offered by the Company in an underwritten offering. Cohen &amp; Company Capital Markets, a division of J.V.B. Financial Group LLC, acted as lead book-runner, and Northland Capital Markets acted as joint book-runner for the offering. A registration statement relating to the securities was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on May 20, 2025.

IPOs

AACIU

Armada Acquisition Corp. II to Begin Trading Shares and Warrants Separately Starting June 24

CERo Therapeutics shares are trading higher after the company received FDA Orphan Drug Designation for CER-1236 for the treatment of acute myeloid leukemia.

Biotech

Health Care

General

MLYS

Mineralys Therapeutics Announced Topline Data From Its Phase 2 Explore-CKD Trial Of 25 mg Of Lorundrostat For Hypertension And Comorbid CKD, The Trial Met The Primary Endpoint And Demonstrated Clinically Meaningful Reductions In Both Systolic Automated Office Blood Pressure And Urine Albumin-to-creatinine Ratio, And Demonstrated A Favorable Safety And Tolerability Profile

VTYX

Ventyx Biosciences Announces Topline Results From Phase 2a Study Of VTX3232 In Early-Stage Parkinson's Disease; Says VTX3232 Resulted In Reductions In NLRP3-Related Biomarkers In CSF And Plasma

Press Releases

Powerfleet Sets Third Quarter Fiscal 2025 Conference Call for Monday, February 10, 2025, at 8:30 a.m. ET

Earnings

Powerfleet Reports Third Quarter 2025 Financial Results

Powerfleet Unity Named #1 Global Platform & Solution Portfolio in its Market by ABI Research

Powerfleet Launches Unity's AI-Driven In-Warehouse Solutions in partnership with TELUS, Unlocking Major Growth Potential

Powerfleet to Present at the 37th Annual Roth Conference

/C O R R E C T I O N -- Powerfleet/

Powerfleet to Attend the 20th Annual Needham Technology, Media, & Consumer Conference

Powerfleet Provides Business Update Ahead of Upcoming Craig-Hallum and William Blair Conferences

Contracts

EverDriven Expands AI Video Safety Partnership with Powerfleet to Enhance Student Transportation Across 34 States

Powerfleet Reports Annual FY2025 Results: A Breakout Year of Strategic Transformation and Scaled Growth

Comments

PowerFleet

PowerFleet (AIOT) Opzioni

PowerFleet (NASDAQ:AIOT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO